Clinical Trial Update: Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating camrelizumab in combination with apatinib and eribulin versus physician's choice chemotherapy in metastatic triple-negative breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)
• Eribulin (eribulin mesilate)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Breast Cancer Stage IV, Triple -Negative Breast Cancer | Phase 3 | Status: RECRUITING